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Effects of Polymer 3D Architecture, Size, and Chemistry on
Biological Transport and Drug Delivery In Vitro and in
Orthotopic Triple Negative Breast Cancer Models
Amanda K. Pearce,* Akosua B. Anane-Adjei, Robert J. Cavanagh, Patricia F. Monteiro,
Thomas M. Bennett, Vincenzo Taresco, Phil A. Clarke, Alison A. Ritchie,
Morgan R. Alexander, Anna M. Grabowska, and Cameron Alexander*
The size, shape, and underlying chemistries of drug delivery particles are key
parameters which govern their ultimate performance in vivo. Responsive
particles are desirable for triggered drug delivery, achievable through
architecture change and biodegradation to control in vivo fate. Here,
polymeric materials are synthesized with linear, hyperbranched, star, and
micellar-like architectures based on 2-hydroxypropyl methacrylamide (HPMA),
and the effects of 3D architecture and redox-responsive biodegradation on
biological transport are investigated. Variations in “stealth” behavior between
the materials are quantified in vitro and in vivo, whereby reduction-responsive
hyperbranched polymers most successfully avoid accumulation within the
liver, and none of the materials target the spleen or lungs. Functionalization of
selected architectures with doxorubicin (DOX) demonstrates enhanced
efficacy over the free drug in 2D and 3D in vitro models, and enhanced
efficacy in vivo in a highly aggressive orthotopic breast cancer model when
dosed over schedules accounting for the biodistribution of the carriers. These
data show it is possible to direct materials of the same chemistries into
different cellular and physiological regions via modulation of their 3D
architectures, and thus the work overall provides valuable new insight into
how nanoparticle architecture and programmed degradation can be tailored
to elicit specific biological responses for drug delivery.
1. Introduction
For disease targets such as cancer, polymeric nanocarriers have
been shown to be effective for achieving site-specific drug de-
livery while minimizing off-target toxicity.[1–3] Typically, small
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molecule chemotherapy drugs have poor in
vivo properties, such as a short blood half-
life, rapid clearance through metabolism,
degradation or activation of an immune
response, and poor accumulation in cells
due to poor blood flow and drug efflux
pumps.[4] The use of polymers as drug car-
riers aims to overcome these drawbacks
through achieving longer circulation times,
enhanced uptake in disease sites and in-
creased specificity of delivery.[5–7] However,
in order to obtain selective tumor uptake
of nanoparticle drug carriers, the delivery
systems must meet several criteria, such
as an appropriate size range for diffusion
out of the vasculature, prolonged circula-
tion time in the bloodstream to allow for ef-
ficient uptake, reduced clearance from the
bloodstream by avoidance of recognition by
macrophages, and stability of the carrier
during circulation.[8,9] Previous literature
suggests that while larger nanocarriers have
prolonged circulation times in the blood,
particles over ≈100 nm suffer from poor
tumor penetration, particularly in the case
of poorly vascularized and necrotic/hypoxic
tumors.[10] Conversely, particles of a size
range less than 30 nm possess good tumor penetration prop-
erties, however the blood circulation times are often decreased
due to the smaller size.[11,12] In addition, it has been observed
that nanoparticle properties such as chemistry, size, shape, and
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aspect ratio all have an effect on pharmacokinetics, tumor pene-
tration and organ accumulation.[13–17] These concepts have been
reviewed in recent years due to the importance of achieving
the appropriate trade-off between nanoparticle characteristics to
achieve both prolonged circulation and good penetration into a
solid tumor mass.[18–20] However, while there have been inves-
tigations of many nanoparticle sizes and shapes, there remain
questions relating to how nanoparticles of specific sizes and ar-
chitectures, but retaining the same surface chemistry behave in
in vivo environments.
The surface chemistry presented by nanoparticle drug delivery
systems to the local biological environment is known to be of cru-
cial importance for achieving prolonged circulation within the
bloodstream.[21] Typically, polyethylene glycol (PEG)-based poly-
mers are utilized for their well-documented stealth properties in
vivo to prevent the nonspecific adsorption of serum proteins and
shield from receptor mediated uptake by the reticuloendothelial
system (RES).[22,23] However, it has also been observed that there
are antibodies produced in the body that recognize PEGylated
materials (anti-PEG Abs) resulting in a reduced treatment effi-
cacy, as well as an increased risk of adverse side effects to the ma-
terials after administration.[24] As a result, a variety of alternative
synthetic polymers have been investigated as coatings or shell
materials for drug delivery nanoparticles, such as poly(amino
acid)s,[25,26] poly(2-oxazoline)s,[27,28] poly(glycerol),[29,30] and
poly(N-(2-hydroxypropyl)methacrylamide) (pHPMA).[31,32] The
potential of poly(N-(2-hydroxypropyl)methacrylamide) for bio-
logical applications was first highlighted by Kopeček et al. in the
1970s.[33,34] Since then, examples of pHPMA–drug conjugates
have been widespread in the literature including reports of use
in clinical trials[35–38] and these continue to show promise in the
field.[39–41]
Particular disease sites present inherent abnormalities; in tu-
mor tissues these include low pH, hypoxia, high temperature,
over-expressed proteins and enzymes and elevated levels of re-
active small molecules such as metabolites and reactive oxygen
species (ROS), which provide opportunities for site-specific deliv-
ery of therapeutics, as well as stimuli for controlled degradation
of the nanocarriers.[42–44] Particularly, the higher concentrations
of glutathione (GSH) found in the microenvironment of certain
tumor types, and especially those of certain breast cancers, can
be exploited through the inclusion of disulfide bonds within a
polymeric system.[43,45,46] Following accumulation of a nanopar-
ticle carrier within a tumor site, the enhanced local GSH con-
centration can promote polymer breakdown through cleavage of
the disulfide bonds.[47,48] Another commonly exploited stimulus
for tumor-targeted delivery is the localized acidic environment of
tumors, with pH ranges of ≈4.5–6.5, providing opportunity for
triggered release through acid-labile linkages.[49–54]
In this work, the effects of differing hydrodynamic size, phys-
ical conformations and programmed biodegradation of drug de-
livery nanomaterials formulated from HPMA is investigated,
with reference to the internalization of the materials in cell
lines, in transit in the body, and in a selected subset, the anti-
tumor efficacy in a relevant aggressive orthotopic triple negative
breast cancer (TNBC) model. While polymeric HPMA materi-
als have been previously studied as drug delivery carriers, the
majority of materials have been synthesized through free-radical
polymerizations.[55,56] More recently, pHPMAs have been syn-
thesized through controlled radical polymerization techniques,
namely, reversible addition fragmentation chain transfer (RAFT)
polymerization, giving greater control over the molecular weights
of the resultant materials, and providing access to more versatil-
ity in the final structures that can be produced.[39,57–60] Based on
the potential of pHPMA-based polymeric drug delivery polymers,
we aimed to exploit the range of architectures and monomer com-
patibility provided by RAFT polymerization to thoroughly investi-
gate if materials of the same chemistries can be directed into dif-
ferent cellular and physiological regions via modulation of their
3D architectures and size, thus providing crucial new insight into
tailoring of nanomaterials to elicit specific biological responses
for drug delivery.
To achieve this, four target polymer architectures were syn-
thesized by RAFT polymerization to produce materials with the
same underlying chemistries, in order to isolate the effects of
the physical variations. Hyperbranched polymers were chosen as
the initial architecture of materials to investigate based on their
known potential for tumor targeting and uptake in vivo.[61,62] Fur-
ther to this, larger architectures were proposed, namely star, high
molecular weight linear and core-crosslinked micellar polymers.
A combination of nondegradable hyperbranched and redox-
responsive architectures were synthesized through parallel syn-
thetic routes in order to access a wide size range of materials
from 5 to 60 nm with multiple stimuli-responsive mechanisms of
degradation, depicted in Scheme 1. The resultant materials were
screened in vitro for their stability, degradation in reducing envi-
ronments, cytocompatibility and uptake by macrophages, and for
their organ distribution in vivo. As a result of the screening pro-
cess, two lead nanoparticles were selected for further functional-
ization with a model anticancer drug doxorubicin via hydrazone-
linker conjugation on the nanoparticles. The potency of the poly-
mer prodrug in comparison to free drug was evaluated in vitro
in monolayer and 3D spheroid cultures and in vivo in an ortho-
topic model of triple negative breast cancer. When the dosing
regime was adjusted to account for the varying distribution ki-
netics, enhanced efficacy in terms of reductions in tumor volume
were demonstrated compared to free DOX, highlighting both the
role of polymer structure in modulating biodistribution and the
potential of these delivery systems for breast cancer therapy.
2. Results and Discussion
2.1. Synthesis of pHPMA in Different Architectures
Synthetic routes were developed that allowed production of a set
of pHPMA materials from a small set of four starting monomers
and two chain transfer agents, using an aqueous RAFT poly-
merization strategy to allow construction of the target architec-
tures through minimal variations of the synthetic conditions
(Scheme 1). In this way, the influence of the physical factors
could be investigated while maintaining the same particle chem-
istry presented by the polymers in biological environments. In
particular, the proposed synthetic routes and architectures were
designed to lead to unimolecular or core-crosslinked nanoparti-
cles, giving the possibility to investigate a range of surface topolo-
gies, chemical group density, ability to conjugate drugs and a
wide accessible particle size range of interest for drug delivery
applications, while still maintaining a high stability in solution
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Scheme 1. Parallel synthetic routes were developed using reversible addition fragmentation chain transfer polymerization (RAFT) of HPMA for the
synthesis of materials with both varying architectures and increasing physical sizes. Hyperbranched through to micelle structures resulted in particles
of a size range 5–60 nm, maintaining the same surface chemistries. Materials featuring disulfide bonds are indicated by SS in the nomenclature.
and thus clinical applicability. Two classes of materials were syn-
thesized: nondegradable pHPMAs in hyperbranched architec-
tures as control materials, as well as redox-responsive architec-
tures featuring disulfide bridges (SS), allowing disassembly of
the polymer architectures in the intracellular milieu of breast
cancer cells which overexpress GSH. A central disulfide bridge
was conferred upon the redox-responsive materials through the
design of cystamine bismethacrylamide (CBMA) and a degrad-
able bis-RAFT agent (4-cyanopentanoic acid)-4-dithiobenzoate-
SS-4-cyanopentanoic acid)-4-dithiobenzoate, CADB-SS-CADB),
which facilitated the synthesis of varying 3D nanomaterials with
degradable regions as the focal point of each architecture. This
ensured biodegradability through disassembly of the parent poly-
mer structure to produce smaller intact linear fragments of the
pHPMA backbone, and thus predictable breakdown products
and profiles. The further incorporation of a t-butoxycarbonyl
(boc)-protected hydrazide methacrylate (tBHM) into the redox-
responsive architectures provided both a degree of hydrophobic-
ity and the capability for covalent attachment of chemotherapeu-
tics.
Each final polymer had a minimum monomer ratio of
80 mol/mol% HPMA, in order to ensure overall water solubil-
ity of the materials,[63] as well as stealth properties in vivo, and
up to 20 mol/mol% of the tBHM units. Hyperbranched poly-
mers (HBs) were synthesized as previously described,[63] initially
employing a nondegradable bifunctional ethylene methacry-
lamide (EDMA) as the crosslinking unit, resulting in small, uni-
molecular globular particles (hyperbranched small; HB-HPMA-
S). The branched core was also further chain extended with
additional HPMA to yield larger particles (hyperbranched large;
HB-HPMA-L). To confer redox-responsiveness to the same ar-
chitecture, the synthesis was repeated employing CBMA as the
crosslinking unit, resulting in HBs with a high degree of redox-
reducible branching points with a 5 mol% (hyperbranched-SS
low hydrophobic; HB-SS-LH) and 20 mol% incorporation of
tBHM (hyperbranched-SS high hydrophobic; HB-SS-HH).
Star-type architectures were achieved through chain extension
of the HB-SS-HH with additional HPMA at a low (50) and a high
(100) target degree of polymerization (DP), resulting in slightly
larger unimolecular particles (Star-SS small, Star-SS-S; Star-SS
large, Star-SS-L) with a nondegradable HPMA corona. A high
molecular weight linear polymer was synthesized as a random
copolymer of HPMA and tBHM at an 80:20 mol/mol ratio, uti-
lizing CADB-SS-CADB to provide a central disulfide bridge in
the polymer main chain (Linear-SS). Finally, core-crosslinked
micelles of AB block copolymers were achieved by utilizing a
polymerization-induced self-assembly (PISA) process. First, an
HPMA macroRAFT agent was synthesized, followed by chain
extension with tBHM to form the block polymer in water, driv-
ing self-assembly of the polymers into micelles as the DP of
the tBHM block increased. Crosslinking was achieved in situ
through inclusion of CBMA during the second polymerization
step to form micelles stabilized by disulfide links (Micelle-SS).
The synthetic schemes toward the final pHPMA materials are
depicted in Scheme 1.
2.2. Physical Characterization of pHPMAs
The absolute molecular weight of each polymer (without refer-
ence to linear standards) was measured through aqueous size
Adv. Healthcare Mater. 2020, 9, 2000892 2000892 (3 of 14) © 2020 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advhealthmat.de
Figure 1. A) Physical characterization of varying architecture pHPMAs. B) Dynamic light scattering measurements. C) Transmission electron microscopy
images of a) HB-HPMA-S, b) HB-HPMA-L, c) HB-SS-HH, d) Star-SS-L, e) Linear-SS, and f) Micelle-SS (scale bar: 100 nm). D) Degradation studies of
redox-responsive pHPMAs showing shifts in DLS traces for the HB-SS-HH over time and E) change in diameter of all architectures over time in 10 ×
10−3 m GSH after incubation at 37 °C.
exclusion chromatography - multi-angle laser light scattering
(SEC-MALLS) (dn/dc = 0.158) (Figure 1A). Due to the com-
plex nature of the polymer architectures synthesized in this
work, molecular weight analysis through SEC-MALLS was most
representative of the absolute molecular weight, rather than
Mn calculated through proton nuclear magnetic resonance
spectroscopy(1H NMR) (Figures S1 and S2, Supporting Informa-
tion). The nondegradable hyperbranched polymers, HB-HPMA-
S and HB-HPMA-L, had the smallest molecular weights of 15
and 22 kDa, respectively. By utilizing the disulfide crosslinker,
CMBA, as well as a higher mol ratio of crosslinker and RAFT
agent to HPMA, a larger overall molecular weight could be
achieved for the HB-SS-LH and HB-SS-HH, of 50 and 58 kDa,
respectively. Following chain extension of the HB-SS-HH with
additional HPMA, larger star architectures, Star-SS-S and Star-
SS-L, of molecular weights 86 and 122 kDa were reached. The
absolute molecular weight of the linear polymer, Linear-SS, was
257 kDa. Finally, the core-crosslinked micelles, Micelle-SS, syn-
thesized through dispersion polymerization showed a single self-
assembled species by SEC, with molecular weight quantification
of 3,000 kDa.
All materials were sized using dynamic light scattering (DLS),
confirming all polymers were present in solution (phosphate
buffered saline, PBS) as a monodisperse population with a range
of hydrodynamic diameters from 5 nm for the nondegradable
HBs up to 60 nm for the core-crosslinked micelles (Figure 1B).
To corroborate the presence of a single nanoparticle population
from the DLS analysis, all polymers were also imaged using
transmission electron microscopy (TEM), which confirmed that
all polymer architectures were discrete and uniform globular en-
tities (Figure 1C). It could thus be concluded that in addition
to achieving different polymer architectures, a range of physi-
cal sizes and polymer molecular weights were also produced, al-
lowing investigation into the biological effects of these variations
while maintaining the same particle chemistry throughout.
Based on the physical characterization, it was evident that
Linear-SS self-assembled in water, as DLS and TEM both con-
firmed the formation of particulate species of ≈30 nm diameter.
It was hypothesized that the random amphiphilic copolymer was
assembling into flower-like micelle structures as previously de-
scribed due to the presence of the tBHM units.[64–66] To evalu-
ate this, critical micelle/aggregation concentration (CMC/CAC)
measurements were performed using a DLS-based CMC/CAC
method, and the results are shown in Figure S3 (Supporting In-
formation). It could be observed that the linear polymer indeed
exhibited a CMC at ≈4 µg mL−1, thus confirming the ability for
this material to self-assemble. Unexpectedly, a CMC could also be
observed for the star polymers and the core-crosslinked micelles,
at 9 and 12 µg mL−1 respectively,[67] but was not observed for the
hyperbranched polymers. As well as the linear polymers, the star
materials can also be considered to be random copolymers with
both hydrophobic and hydrophilic regions, and so it is likely that
self-assembly can occur in the same way due to association of the
hydrophobic segments as previously described.[67,68]
2.3. In Vitro Stability and Controlled Degradation of pHPMAs
The surface charge, or zeta potential, of a polymeric nanoparticle
is known to influence its behavior in biological environments,
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both in terms of stability of the polymer suspension as well as
interactions with proteins in the body.[69,70] A slightly negative
zeta potential (from neutral to −25 mV) should confer polymeric
nanoparticles with resistance to aggregation and reduced inter-
actions with proteins.[71] Zeta potentials determined for all pH-
PMA materials confirmed a negative surface charge, in accor-
dance with previous literature on pHPMAs. It is interesting to
note that the zeta potential of the linear polymer was closer to
neutral than for the core-crosslinked micelles, despite both ar-
chitectures being self-assembled nanoparticles. We suggest that
the PISA-produced micelles exhibited a denser pHPMA corona,
resulting in the more negative surface charge, in comparison to
a looser flower-micelle self-assembled structure from the linear
random copolymer.[72]
The stability of the pHPMAs to aggregation or disassembly un-
der biologically relevant conditions was assessed using a range of
DLS-based assays, due to the fast response time and ease of de-
tection of aggregation within each sample. For all experiments,
the value of the laser attenuation was kept constant, and thus any
significant changes in stability or aggregation would result in a
change in the DLS peak intensity. First, stability in cell culture
conditions was tested by incubating each material in Dulbecco’s
Modified Eagle Medium (DMEM) at 37 °C, and measuring by
DLS over time. It can be seen in Figure S4 (Supporting Informa-
tion) that all materials were stable for the duration of the experi-
ment, with no significant changes in the DLS traces observed.
The degradation of the redox-responsive pHPMAs through
disulfide cleavage was investigated through DLS using 10 × 10−3
m glutathione (GSH) to mimic the intracellular concentrations
within TNBC cells.[73] Each material was incubated in GSH in
PBS at 37 °C and measured at 1, 24, and 48 h to assess any
changes in size.[74] The linear, star and hyperbranched struc-
tures showed a decrease in diameter over time as expected (Fig-
ure 1D,E) due to disassembly into their smaller linear fragments,
however there was no significant change in the diameter of the
core-crosslinked micelles during the experiment. As the micelles
were core-crosslinked in situ during the polymerization process,
it is likely that the disulfides are embedded deep within the hy-
drophobic core and thus are not very accessible. GSH is a hy-
drophilic molecule (log P −6.4), and as such may be unable to
penetrate into the hydrophobic inner regions of the micelle to in-
duce complete disassembly of the structure. These observed re-
sults may also reflect the high stability and low CAC of the block
copolymer assembly.
Finally, in order to investigate the stability of the pHPMAs
against protein corona binding, and thus induced aggregation
in a protein-rich environment such as within the bloodstream,
a DLS study was performed using bovine serum albumin (BSA)
as the model protein.[75] Two concentrations of BSA in solution
were assayed; 0.2 wt%, which is representative of the protein con-
centration within DMEM culture media with 10% fetal bovine
serum (FBS),[76,77] and 1 wt% to mimic the protein concentration
in animal models.[78] It could be seen at the 0.2 wt% BSA concen-
tration that all nanoparticles were stable to aggregation after 24 h
incubation at 37 °C, with minimal observable changes in the DLS
trace by volume over the course of the experiment (Figure 2C; Fig-
ure S5, Supporting Information). At the higher concentration of
1 wt%, a similar stability was confirmed for all architectures, with
the exception of the Linear-SS. In this case, after incubation with
the BSA, the nanoparticle peak was no longer detected by DLS,
with only peaks due to the BSA observed. As no large-sized peaks
were detected by intensity or volume measurements, this was hy-
pothesized not to be the result of an induced aggregation process,
but rather was attributed to interactions between the BSA and the
linear polymer obstructing the self-assembly process, resulting
in the polymer being present in solution as single chains. Over-
all, resistance to protein corona binding was observed during the
in vitro assays, suggesting the nanoparticles would not be prone
to aggregation within biological environments for subsequent
assays.
2.4. In Vitro Analysis of Toxicity and Macrophage Uptake
The materials in this work were screened for cytotoxicity in two
TNBC cell lines, MDA-MB-231 and MDA-MB-468. In addition,
the effects of the polymers on RAW264.7 macrophage cells were
also evaluated to further characterize cytotoxicity and gain an in-
sight into immune cell evasion and thus the stealth behavior of
the material. For the biological assays, all polymers were labelled
with a cyanine5 fluorescent dye through amide coupling with
the RAFT terminal carboxylic acid groups. A low incorporation
of dye was targeted (≈0.5 per polymer) to reduce any structural
impact of the dye molecules on the nanoparticles.[79] Metabolic
and lactate dehydrogenase (LDH) release assays in the three cell
lines confirmed that no significant toxicity or membrane damage
could be observed over all concentrations tested, with cell viabil-
ities remaining close to 100% after 48 h of incubation at con-
centrations reaching 1 mg mL−1 (Figures S6 and S7, Supporting
Information).
The stealth behavior in vivo and evasion of uptake by
macrophages of the pHPMA materials was initially investigated
in an in vitro macrophage model using RAW264.7 cells,[76,80] in
order to quantify internalization of the nanoparticles over time,
as well as assess any effects of polymer architecture on this be-
havior. As the pHPMAs were of a range of physical architec-
tures and surface zeta potentials, it was expected that the ma-
terials would show a different profile of both time-dependent
and concentration-dependent uptake. Indeed, the two smallest
polymers, the HB-HPMA-S and HB-SS-HH, demonstrated the
most “stealth” behavior, with a very low amount of nanoparti-
cle internalization by macrophages over 4 h (<5 pg per cell).
The HB-HPMA-L and Star-SS-L also demonstrated low levels
of internalization, with less than 10 pg per cell. In compari-
son, the larger sized linear and micellar pHPMAs showed a
significantly higher macrophage uptake over this time period
(≈20 pg per cell), further suggesting a size dependence for this
process. Particularly, it can be seen that there is a difference in
the initial rate of uptake over the first 60 min (Figure 2B) for
the different polymers, with the Linear-SS and Micelle-SS show-
ing the greatest increase, or rate of uptake, during this period.
The observed size dependency of cellular uptake could be at-
tributed to several phenomena; firstly the small nanoparticles
evading recognition by surface receptors on the macrophages,
and in turn decreased susceptibility to phagocytosis.[81] Second,
the smaller sized particles (≤15 nm) may be internalized into
macrophages via fewer pathways than the larger particles. For
example, clathrin- and caveolin-mediated endocytosis have been
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Figure 2. Protein corona binding studies of pHPMAs with A) representative DLS traces of the redox-responsive polymer architectures after incubation
in 0.2 wt% of BSA, confirming stability to aggregation in these conditions. In vitro data depicting B) time-dependent uptake of degradable pHPMAs into
RAW264.7 macrophages at a concentration of 50 µg mL−1 and C, and B) concentration-dependent uptake of degradable pHPMAs after 2 h incubation.
reported to be restricted with small nanoparticles (<50 nm),[82]
and this is believed to be a result of insufficient thermodynamic
driving force for membrane wrapping.[83–85] To obtain increased
driving force to exploit these endocytotic routes, such as that
demonstrated by the larger nanoparticles, the smaller nanopar-
ticles must cluster or aggregate,[82] however stability studies in
cell culture conditions (Figure 2) indicate pHPMA materials are
unlikely to do so.
It is interesting to note that the highest uptake in both time
and concentration-dependence was not observed for the largest
nanoparticles (micelle), but for the linear architecture, reflecting
the results of the BSA assay (Figure 2). Despite having a smaller
size of 30 nm, the zeta potential is −5.47 mV in comparison to
the −20.8 mV for the 60 nm micelle, and thus indicates, in agree-
ment with previous literature, that there is an influence of both
particle size and surface charge in reducing macrophage associ-
ation, and so a balance between the two factors must be achieved
for stealth behavior (Figure S8, Supporting Information).[86] Flu-
orescence microscopy images of the macrophages confirmed that
the observed uptake was intracellular rather than membrane as-
sociation (Figure S9, Supporting Information).
2.5. In Vivo Analysis of Organ Distribution
In vivo biodistribution studies were performed in healthy female
nude mice to characterize the effects of size and shape on or-
gan accumulation, particularly focusing on organ distribution
within clearance pathways such as the liver and kidneys. After
intravenous administration of each material, mice were imaged
in vivo at 1, 4, and 24 h postinjection, and at each time point,
two mice in each group were culled and their organs were im-
aged ex vivo. Representative in vivo images at 4 h postinjec-
tion are depicted in Figure 3A, where it can be seen for the two
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Figure 3. A) Representative in vivo images at 4 h postinjection for the nondegradable hyperbranched polymers. B) Representative ex vivo images of
redox-responsive pHPMA materials at 1, 4, and 24 h postinjection (Br: brain; H: heart; Lu: lungs; Li: liver; P: pancreas; Sp: spleen; K: kidneys; U: urine;
Bl: blood). C) Quantitation of the ex vivo organ data to allow comparison between different architectures, highlighting the fluorescence signal in organs
important for nanoparticle clearance from the bloodstream (n = 2 ± SD) over time. D) Quantitation of the fluorescence signal in the heart at all times,
indicative of circulating nanoparticles (n = 2 ± SD).
nondegradable control polymers, HB-HPMA-S and HB-HPMA-
L, that at this time point there is evidence of clearance of the poly-
meric materials through the renal system, characterized by fluo-
rescent signal within the kidneys and bladder of the mice.
Due to tissue penetration limits of in vivo fluorescence imag-
ing, which limits detailed observation of organ fluorescence in
vivo,[87] the ex vivo images at each time point were also analyzed.
Representative ex vivo images of the redox-responsive polymer
architectures are shown in Figure 3B.
There were obvious variations in the distribution of fluores-
cence signal throughout the different organs after administration
of the polymers, dependent on the architecture, physical size and
surface charge of the materials. The linear polymers, which were
of the highest molecular weight (≈250 kDa) showed high accu-
mulation of signal in the liver, with the least observed fluores-
cence in the kidneys of all the polymers. As the Linear-SS poly-
mer contained only a single disulfide breaking point, the smallest
possible polymer fragment was likely to be ≈125 kDa in size, and
previous literature has shown that linear polymers with molec-
ular weights over 50 kDa show reduced renal filtration and en-
hanced liver uptake.[88] In contrast, for the hyperbranched poly-
mers, which had the lowest molecular weight and physical size,
the intensity of fluorescent signal was greatest in the kidney and
with low liver fluorescence. For the star and micelle materials, the
signal in the liver was increased over that of the hyperbranched
polymers; however, kidney fluorescence was also observed for
both architectures. To probe further the distribution of the pH-
PMA materials through the various organs, regions of interest
(ROI) were drawn around the ex vivo images for semiquantita-
tion. It is important to note that fluorescence imaging in tissues
is only semiquantitative, and therefore fluorescence signal was
expressed as total flux (the radiance (photons/sec) in each pixel
integrated over the ROI area) in order to improve the interpre-
tation of the results. As the organs of most interest were those
Adv. Healthcare Mater. 2020, 9, 2000892 2000892 (7 of 14) © 2020 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advhealthmat.de
involved in clearance of nanoparticles from the bloodstream, the
data for kidneys, liver, spleen, and lungs are presented at each
time point (Figure 3C).
The ROI analysis was able to confirm the qualitative obser-
vations from the ex vivo images, depicting clear changes in
organ distribution across the different pHPMA materials. For
the smallest nondegradable HB-HPMA-S, polymer accumula-
tion was observed to be mostly confined within the kidneys, with
some evidence of accumulation in the liver as well. This sug-
gests that the materials were being primarily cleared through
the renal system, which was as expected for small and flexible
nanomaterials.[71,89] For the larger HB-HPMA-L, this effect was
slightly delayed, likely due to the physical size of 12 nm mov-
ing the materials further beyond the theoretical renal clearance
threshold of ≈6 nm.[90] For the degradable HBs, it can be seen
that all mononuclear phagocytic system (MPS) organs showed
a low amount of fluorescence, with the majority of the fluores-
cence found in the kidneys throughout the course of the experi-
ment. The two redox-responsive hyperbranched polymers, HB-
SS-LH (DH ≈ 8 nm) and an HB-SS-HH (DH ≈ 10 nm), were
comparable in size to the nondegradable HB-HPMA-S (DH ≈
6 nm) and HB-HPMA-L (DH ≈ 12 nm); however, they demon-
strated reduced MPS organ accumulation and increased renal fil-
tration in comparison. This may have been due to fragmentation
of the degradable polymers by reducing species in the body and
subsequent renal clearance, or by avoidance of micropinocytosis
by MPS-resident macrophages. The latter hypothesis is in accor-
dance with the in vitro macrophage uptake, where the HB-SS-
HH materials showed the least uptake in experiments in which
both time-dependent and concentration-dependent internaliza-
tion were evaluated.
For the larger pHPMAs, which contained fewer disulfide links
as well as larger fragments following disassembly as seen by DLS,
the ratio of MPS to renal accumulation increased. The highest
liver uptake was seen for the self-assembled nanoparticles of the
Linear-SS polymer, which was again in accord with the in vitro
assays of high macrophage internalization, despite the initial par-
ticle size falling within the middle of the size range in this study
(30 nm).[91] For this polymer, a high proportion (≈50–70% of the
fluorescence signal) appeared in the liver as well as the lungs at all
time points, with only minimal signal coming from the kidneys
(less than 20% of the signal relative to the other organs) These
data may be suggestive of interactions with serum proteins (as
observed in the in vitro assays with BSA at high protein concen-
trations; Figure S5, Supporting Information), which is known to
result in recognition by macrophages of the MPS, and thus this
polymer was more likely to have increased liver uptake in vivo.[92]
The Star-SS-S (DH ≈ 12 nm) and Star-SS-L (DH ≈ 15 nm) both
showed increased accumulation in the liver rather than the kid-
neys, despite being synthesized from the 8 nm HB-SS-HH core.
This suggests that the covalent attachment of a larger pHPMA
corona reduced the ability of the materials to filter through the
renal system, even after cleavage of the disulfide crosslinks. For
the largest particles, the Micelle-SS (DH ≈ 60 nm), the highest
uptake was in the liver but there was observable signal in the kid-
neys at all time points, and an overall behavior ratio comparable
to the Star-SS materials. This is indicative of disassembly in vivo
into single polymer chains and subsequent renal clearance, even
though the prior in vitro experiments with glutathione did not re-
sult in micellar breakdown over the same time period. It is likely
therefore that the kidney accumulation can be attributed to dilu-
tion of the micelles below the CMC in vivo during circulation, de-
spite the covalent crosslinking, resulting in an equilibrium shift
toward single polymer chains which were then cleared through
the renal system.[93]
It has been reported that the lungs, liver and spleen are the
important sites for nanoparticle clearance by phagocytosis from
the bloodstream, and it can be seen from the ex vivo data that the
spleen signal for all materials was extremely low across all time
points, even for materials that were retained in the liver.[81,94,95]
Furthermore, nanoparticle aggregation or agglomeration in vivo
typically results in significant amounts of accumulation within
the lungs, however it can be seen that lung signal was also low
(and less than 20% of the fluorescence as estimated from the op-
tical imaging) for all materials. These data together imply that all
the pHPMAs investigated were not prone to immune-mediated
uptake and protein-induced aggregation within the bloodstream,
and thus could be considered as candidate stealth nanoparticle
drug carriers for drug delivery.
Finally, the fluorescence signal within the heart was evalu-
ated as a proxy for detecting circulation of nanoparticles within
the body.[96] Figure 3D and Figure S10 (Supporting Information)
show representative signal over time for the pHPMAs, and we
were particularly interested in HB-SS-HH, Star-SS-L, Micelle-SS,
and Linear-SS. Clear differences in circulation lifetimes were ob-
served across these samples. The smallest HB-SS-HH showed
the most rapid clearance from the heart, in line with the high
kidney signal also observed. Unsurprisingly the larger Micelle-
SS showed more prolonged retention in the circulation, while the
Linear-SS showed clearance likely due to opsonization as already
discussed. It was also of note that the Star-SS-L polymer showed
good circulation lifetime despite its small physical size, whereby
minimal organ accumulation was detected at the first time point
indicating it was still in circulation, with significant fluorescence
signal still detected within the heart after 24 h.
2.6. Doxorubicin Conjugation to Candidate pHPMAs
Based on the biodistribution data, two candidate pHPMA archi-
tectures were selected for investigation as drug delivery carri-
ers: HB-SS-HH (DH ≈ 10 nm) and Star-SS-L (DH ≈ 15 nm), as
these two materials were of essentially the same chemical com-
position and similar size, but exhibited very different organ ac-
cumulation and circulation lifetime behavior. We were partic-
ularly interested if these features might allow us to factor out
particle size and chemistry in terms of tissue penetration, and
focus on how biodistribution might then alter ultimate therapeu-
tic effect. In this way, the selection of the two nanoparticles of
similar size but very different in vivo behaviors had potential to
give intriguing insights given that only one variable was being
significantly modified (polymer architecture). The Boc-protecting
groups on the tBHM units within each polymer structure were
removed through trifluoroacetic acid (TFA) deprotection, and
then DOX was attached through the formation of an acid-
labile hydrazone bond to yield the polymer prodrugs (Figure 4A;
Figure S11, Supporting Information). Following purification,
quantification of DOX conjugation was calculated using NMR
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Figure 4. A) Synthetic scheme for the boc-deprotection and DOX attachment to a representative pHPMA, B) DLS traces of the polymer prodrugs, C)
quantification of DOX attachment by NMR and UV–vis (488 nm) and characterization by DLS, D) stability and release of DOX from the polymer prodrugs
at pH 5.5 and 7.4 conditions, and E) growth inhibition curves of free DOX and the polymer prodrugs against MDA-MB-231 cells after 48 h incubation.
spectroscopy to integrate the signals from the drug compared
with the polymer backbone (Figure S12, Supporting Informa-
tion) and UV–vis analysis using a standard curve of DOX⋅HCl
(Figure S13, Supporting Information), which revealed function-
alization in the range of 9–12 mol% (Figure 4C). The polymer
prodrugs were sized by DLS, giving size values of approximately
DH = 12 nm for HB-SS-HH-DOX and DH = 18 nm for Star-SS-
L-DOX, indicating a slight increase in the hydrodynamic volume
as a result of the drug attachment (Figure 4B). The stabilities
of the polymer prodrugs were assessed through the DMEM and
BSA assays described above, which confirmed that the presence
of the DOX within the nanoparticle structure did not have any
impact on the stability, with both particles remaining as discrete
populations in both conditions over 48 h (Figure S14, Support-
ing Information). Finally, an in vitro buffer release experiment
was conducted to determine the stability of the drug conjugation,
as well as their DOX release kinetics under physiologically rele-
vant conditions of pH. Each nanoparticle was dialyzed in either
pH 5.5 (endosome conditions) or 7.4 (serum conditions) phos-
phate buffer at 37 °C for 72 h, and the buffer measured at pe-
riodic intervals for DOX concentration. Quantification of DOX
release showed that at pH 7.4 the prodrugs released up to 10%
over the time frame of the experiment, however this value in-
creased to 55% for the Star-SS-L-DOX and up to 95% for the HB-
SS-HH-DOX, with no burst release and calculated half-lives of
≈14 h (Figure 4D).
2.7. In Vitro Analysis of Drug Delivery Efficacy in 2D and 3D
Models
The ability for the polymer prodrugs to successfully deliver DOX
into cells, and any variations that resulted from different ar-
chitectures, was evaluated in the MDA-MB-231 TNBC cell line.
Dose-response curves of DOX toxicity were produced over 48 h
incubation at varying concentrations of free drug and both drug-
loaded nanoparticles. It can be seen in Figure 4E that the at-
tachment of DOX to the nanoparticles resulted in a significantly
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improved therapeutic effect, with a decrease in the half maxi-
mal inhibitory concentration (IC50) values from 0.23 × 10−6 m
for free DOX to 0.059 × 10−6 and 0.051 × 10−6 m for the HB-SS-
HH-DOX and Star-SS-L-DOX respectively. MDA-MB-231 cells
have been demonstrated to exhibit resistance to doxorubicin, this
improvement in efficacy was hypothesized to be the result of
more specific trafficking of the drug into the cells and thus an
increased DOX intracellular concentration.[97–99] Cellular uptake
studies evaluating polymer internalization via fluorescence mi-
croscopy suggested that DOX trafficked to intracellular compart-
ments when attached to polymers in a manner different to those
of the free drug (Figure S15, Supporting Information). After 1 h
incubation of HB-SS-HH-DOX in MDA-MB-231 cells, colocaliza-
tion of the cyanine5 (Cy5) and DOX signals was observed, with
observed punctate staining indicative of active internalization
pathways and discrete intracellular locations, confirming that the
nanoparticles were able to deliver the doxorubicin to vesicular
compartments within the cells. Images at 2 and 4 h of uptake
suggested delivery of doxorubicin into the nucleus through cleav-
age of the hydrazone bond; at 2 h some doxorubicin signal was
observed in the nucleus and by 4 h the doxorubicin was almost
entirely in the nucleus. Further magnification at 2 h of uptake
confirmed these observations, with clear endosomal staining of
both Cy5 and DOX and also signals of doxorubicin within the nu-
cleus colocalizing with the 4′,6-diamidino-2-phenylindole (DAPI)
stain (Figure S16, Supporting Information).
In order to investigate the ability of the polymer prodrugs to
improve delivery of DOX within more tissue-like environments,
a 3D spheroid culture model was used. 3D spheroid models are
more representative of the tumor environment in vivo, and al-
low the effects of cell–cell interactions and the dense extracellu-
lar matrix (ECM) network typically observed in solid tumors to be
evaluated for their impact on nanoparticle delivery. Accordingly,
3D spheroids of MDA-MB-231 were cultured for 4 days and con-
firmed by optical imaging (Figure 5A). The spheroids were dosed
with blank NPs, free DOX or the polymer prodrugs and images
of the spheroids were taken daily for quantification of growth or
growth inhibition through volume analysis, and after 72 h overall
cytotoxicity was evaluated (Figure S18, Supporting Information).
It can be seen in Figure 5A that for the control spheroids,
which received no treatment, the 3D mass continued to grow
over the course of the experiment reaching over 100% volume
increase. Nondrug loaded nanoparticles, as expected, showed no
toxicity and no inhibition of spheroid growth (Figure S17, Sup-
porting Information). Free DOX was able to inhibit the growth of
the spheroids at a concentration of 1× 10−6 m after 72 h, and from
the optical images it was observed that this reduction in volume
was due to cell death on the periphery of the spheroids. Impor-
tantly, both HB-SS-HH-DOX and Star-SS-L-DOX were observed
to inhibit spheroid growth at a lower concentration than the free
drug, at 0.01 × 10−6 and 0.1 × 10−6 m in DOX, respectively. Of
particular significance, at the highest concentration tested (10 ×
10−6 m), the polymer prodrugs were able to induce complete de-
struction of the spheroid structure, a phenomenon not observed
for the free drug. This gave further confirmation of the ability not
only for the nanoparticles to deliver doxorubicin into the cells, but
also to penetrate deep within a tumor-like solid mass to ensure
cell kill beyond the surface layers and subsequent loss of spheroid
structure. Interestingly, the two polymer prodrugs showed com-
parable behavior, with IC50 values in the 3D model of 0.36 ×
10−6 m for the HB-SS-HH-DOX and 0.52 × 10−6 m for the Star-
SS-L-DOX (Figure 5C). These results suggested that despite the
slower drug release profile of the Star-SS-L-DOX in buffer con-
ditions and the reduced IC50 value in the 2D monolayer model,
this nanoparticle was still efficacious in a 3D model.
2.8. Assessment of Drug Delivery Efficacy in a Murine Orthotopic
Model of Triple Negative Breast Cancer
Based on these promising results, in vivo therapeutic efficacy
studies were performed. An orthotopic model of TNBC was es-
tablished in female nude mice using MDA-MB-231 cells trans-
fected with luciferin, to provide bioluminescence imaging as well
as physical measurements of tumor growth over time. Once pal-
pable tumors were confirmed, mice were dosed according to two
regimes. In the first schedule, the mice were dosed 3× a week for
2 weeks at a value of DOX (as free drug or as dosed equivalent)
of 4 mg kg−1 (Figure 5D). In the second schedule, the mice were
dosed three times in the first week, and then 1× per week for the
next 2 weeks, at a value of DOX (as free drug or as dosed equiva-
lent) of 2 mg kg−1 (Figure 5E,G). For both experiments, mice were
observed daily for adverse effects, body mass and tumor volumes,
continuing for a further 2 weeks following the treatment period.
At 28 days after the initial dosing, all mice were culled and the
final tumors analyzed, as well as the hearts and spleens as indi-
cators of systemic DOX toxicity. As apparent from Figure 5D, in
the first schedule all treatment regimens reduced tumor growth
relative to vehicle control, but the Star-SS-L-DOX was less effec-
tive than HB-SS-HH-DOX and free DOX alone.
It can be seen from Figure 5E that for the second schedule,
again all treatment regimens reduced tumor growth relative to
vehicle control, however in this case both nanoparticle treatment
groups were able to improve on the therapeutic effect of the free
drug, reducing tumor growth to 138% for the HB-SS-HH-DOX
(p* < 0.05 vs free DOX) and 127% for the Star-SS-L-DOX (p**
< 0.01 vs free DOX). We attribute the difference in relative effica-
cies of the polymers in the two studies to the different time peri-
ods in between dosing, and their likely distributions throughout
the body in comparison with the free doxorubicin. It is known
that in humans doxorubicin has a triphasic distribution profile
owing to plasma protein binding, but studies have reported that
more than 90% of the injected dose is eliminated within a day.[100]
For mice, a similar percentage of free doxorubicin is lost within
12 h, thus a more frequent 48 h dosing schedule, as that shown
in Figure 5D, was likely to result in greater drug concentrations
in the tumors compared to the 3–4 day dosing interval study, as
shown in Figure 5E. In addition, as the dose of doxorubicin was
lowered to 2 mg kg−1 in the experiments reported in Figure 5E,
the tumors likely received a much lower dose, resulting in lim-
ited ability to reduce the tumor volume. By contrast, the longer
circulating polymer pro-drugs were relatively more effective at
preventing tumor growth than free doxorubicin in the longer-
interval dosing study, which is consistent with previous literature
on pHPMA–DOX conjugates.[41,101–103]
We considered it likely that the nanoparticle dosed groups
could achieve a longer residence time within the tumor mass
than the free drug; indeed, after the dosing period the tumors
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Figure 5. A) Optical microscopy images of MDA-MB-231 spheroids at 4 and 7 day incubation after control (no treatment), free DOX and polymer prodrug
treatments, B) %volume change of spheroids between 0 and 72 h incubation based on volume analysis, and C) spheroid growth inhibition curves of
free DOX and the polymer prodrugs after 72 h incubation. Orthotopic model of TNBC was established in female nude mice using MDA-MB-231 cells
transfected with luciferin D) 4 mg kg−1 dosing: in vivo tumor volumes as measured by calipers after frequent dosing (every 2 days for 2 weeks) and
E) 2 mg kg−1 dosing: tumor volumes as measured by calipers for the wider dosing interval study (5 doses over 3 weeks). The dotted lines indicate the
dosing period. F) masses of key organs relative to tumor are given for the wider dosing interval study and G) mouse body weights throughout the wider
interval dosing study.
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in the DOX group continued to grow, however both the HB-SS-
HH-DOX and Star-SS-L-DOX groups showed a far slower rate of
regrowth in this recovery period. The ex vivo analyses of tumor
mass and volume showed that the tumors from both nanoparti-
cle treatment groups were significantly smaller than those treated
with free DOX (Figure 5F). To provide further insights, a 24 h
biodistribution study of both nanoparticle groups confirmed flu-
orescent signal, and thus localization, within the regions of the
tumors after 24 h, providing supporting evidence of the DOX ef-
ficacy (Figure S19, Supporting Information).
A key driver in the development of nanomedicines for can-
cer drug delivery is evaluation of the systemic toxicity as a re-
sult of the administered drug. The toxicity can be evaluated via
measurements of body mass in experimental animals, and more
relevantly to human doxorubicin use by evaluating mass changes
in the heart and spleen.[104,105] The data in Figure 5F show that
the body mass of the DOX treatment group increased at a slower
rate than all other groups, only reaching 106% of their orig-
inal body mass over the course of 28 days, in comparison to
≈115% for both nanoparticle dosed groups, in agreement with
prior literature.[106–109] In addition, there was some evidence of
decrease in the average mass of the spleen in the mice of the dox-
orubicin group, which is another indication of drug toxicity that
was not present in any other experimental groups (Figure 5F).
These results suggested that the polymer prodrugs did not cause
DOX release during circulation to a detrimental extent, and there-
fore did not impart nonspecific toxicity to the animals.
When the orthotopic model data is considered as a whole, the
most intriguing observations were those revealing the difference
in efficacy between HB-SS-HH-DOX and Star-SS-L-DOX over
the different dosing regimens. While both formulations exhib-
ited very similar potencies in 3D spheroids, in vivo HB-SS-HH-
DOX (DH = 12 nm) had been shown to accumulate more in the
kidneys while Star-SS-L-DOX (DH = 18 nm) was more retained
in the liver (Figure 3B,C), and drug release was faster from the
HB-SS-HH-DOX than the Star-SS-L-DOX polymers (Figure 4D).
It is likely that the better efficacy of HB-SS-HH-DOX in the first
dosing regime was due to a higher doxorubicin dose reaching
the tumors on account of the longer circulation time compared
to the free drug and the faster release from the carrier compared
to the Star-SS-L-DOX. In the latter case, it is likely that increas-
ing the dose made no difference to the efficacy as even at the
higher amounts administered, the release of DOX was not suffi-
cient to generate the same amount of drug in the tumors as that
of HB-SS-HH-DOX. Thus, the change in efficacy of the polymers
compared to free drug at higher drug equivalents administered
(Figure 5D: 4 mg kg−1 compared to 5E: 2 mg kg−1), which at first
seems counter-intuitive, can be at least partly explained by the
difference in the in vivo residence times of the drugs and carri-
ers, and by the different release rates from the carriers. In turn,
the different architectures of the HB-SS-HH-DOX and Star-SS-
L-DOX polymers can account for the altered rate of doxorubicin
release, as the cleavage of the hydrazone bond required penetra-
tion of acidic media into the core of the polymers, and an initial
influx of GSH to “open up” the polymer network by cleaving the
disulfide links maintaining the chains together.
These data highlight the complexities of responsive polymer
structure, conformation, biodistribution and drug release pro-
files pertaining to anticancer efficacy. They also indicate the im-
portant trade-off between nanoparticle size to achieve both pro-
longed circulation and good penetration into a solid tumor mass,
and the effects that changing polymer architectures can have in
altering biodistribution and drug release even when the under-
lying chemistries are almost identical. The extensive data in this
study provide key pointers to polymer design such that drug re-
lease rates can be “dialled in,” dosing schedules can be planned
which maximize the therapeutic effects of the formulations while
reducing systemic toxicity and as such the ability to program drug
release and biodistribution from fine control of polymer architec-
ture is extremely promising for future delivery studies.
3. Conclusions
Here, the effect of size and 3D architecture of identical under-
lying chemistries pHPMA materials on in vitro transport and
in vivo organ accumulation was investigated. Through aqueous
RAFT polymerization, we successfully produced a small set of
polymer materials spanning a size range from 5 to 60 nm, with
linear, hyperbranched, star, and self-assembling micellar archi-
tectures, allowing for investigation of the contribution of archi-
tecture, size and degradability on in vivo particle distribution by
maintaining the same materials chemistry throughout. The re-
sulting materials showed promising behavior as stealth carriers
both in vitro and in vivo. In vitro macrophage uptake studies
demonstrated significantly different behaviors governed by sur-
face zeta potential and physical size. The smaller hyperbranched
structures were taken up by macrophages to a significantly lower
degree than the larger hyperbranched and star particles, in agree-
ment with reduced MPS uptake and increased renal clearance
in vivo. Conversely, the larger self-assembled micelles and lin-
ear polymers were more recognized by macrophages in vitro and
showed higher MPS/renal clearance ratios in vivo. Functional-
ization of two lead nanoparticles, HB and Star, with a model an-
ticancer drug doxorubicin validated the promise of the nanopar-
ticles in this work for drug delivery applications. Both polymer
prodrugs had improved efficacy over free drug in 2D and 3D cell
culture models and, when dosed at appropriate schedules, in an
orthotopic model of human TNBC in mice. These are promising
results for the polymer-drug conjugates in this work in terms of
preclinical efficacy in an aggressive cancer model, justifying fu-
ture investigations in comparison with current clinical standards
of care formulations such as Doxil, to better inform design of
the investigated carriers to aid practical application and poten-
tial translation. By tuning polymer structures to assemble into
different conformations and then disassemble into specific size
ranges, we have shown it is possible to direct materials of essen-
tially the same chemistries into different cellular and physiolog-
ical regions, and thus open new routes to targeted nanomaterial
diagnostics and/or therapeutics.
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Res. 1987, 21, 1341.
[32] R. Duncan, Nat. Rev. Cancer 2006, 6, 688.
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